Drugs / Botulinum Neurotoxin Type A
Botulinum Neurotoxin Type A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02964728 | Nov 2015 → May 2016 | burning mouth syndrome | Presidio Ospedaliero Garibaldi-Centro | Completed | No outcome recorded |
| Phase 2 | NCT00765375 | Sep → Dec 2008 | acne | DeNova Research | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01489904 | Nov 2011 | cerebral palsy | Hospital Vall d'Hebron | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07160699 | Oct 2025 → Oct 2026 expected | — | Technical University of Bern | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOTULINUM NEUROTOXIN TYPE-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489904 ↗ |
| Known as | Botulinum toxin type A | “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 |
| Known as | BTX-A | “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 |
| Modality | Protein / enzyme biologic | “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 |
| Route | Other | “topical injection” NCT02964728 ↗ |